Skip to main content
Erschienen in: Clinical and Experimental Nephrology 3/2018

01.06.2018 | Original article

Risk factors of ceftriaxone-associated biliary pseudolithiasis in adults: influence of renal dysfunction

verfasst von: Aya Imafuku, Naoki Sawa, Akinari Sekine, Masahiro Kawada, Rikako Hiramatsu, Masayuki Yamanouchi, Eiko Hasegawa, Noriko Hayami, Jyunichi Hoshino, Yoshifumi Ubara, Kenmei Takaichi

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Ceftriaxone (CTRX) is a known cause of biliary pseudolithiasis (BPL) mainly in children. Biliary elimination of CTRX increases in patients with renal dysfunction. However, the influence of renal dysfunction on the incidence of CTRX-associated BPL has not been well investigated. The aim of this study was to investigate the cumulative incidence of CTRX-associated BPL in adults and to assess if renal dysfunction is a risk factor.

Methods

We retrospectively analyzed the medical records of 478 patients treated with CTRX to assess the incidence and risk factors of CTRX-associated BPL. We examined age, sex, body weight, dosage, and duration of CTRX therapy, and the concentrations of serum creatinine, estimated glomerular filtration rate (eGFR), albumin, and serum calcium in all the patients. The cumulative incidence of BPL was calculated using a competing risk model. The multivariate analysis of each variable for the development of BPL was assessed by a Cox proportional hazards model.

Results

A total of 362 patients (75.7%) had renal dysfunction (eGFR: < 60 mL/min). The cumulative incidence of BPL in patients with renal dysfunction was significantly higher than that in patients with normal kidney function (4.1 vs. 0.6%, p = 0.017). Renal dysfunction (Hazard ratio (HR) 8.14, 95% CI 1.05–63.0, p = 0.045) and female sex (HR 5.35, 95% CI 1.17–24.5, p = 0.031) were independent risk factors of CTRX-associated BPL, which was confirmed using multivariate analysis (renal dysfunction: HR 7.93, 95% CI 1.04–60.5, p = 0.046) (female sex HR 4.65, 95% CI 1.03–21.1, p = 0.046).

Conclusions

Renal dysfunction is an independent risk factor of CTRX-associated BPL in adults.
Literatur
1.
Zurück zum Zitat Arvidsson A, Alvan G, Angelin B, Borga O, Nord CE. Ceftriaxone: renal and biliary excretion and effect on the colon microflora. J Antimicrob Chemother. 1982;10:207–15.CrossRefPubMed Arvidsson A, Alvan G, Angelin B, Borga O, Nord CE. Ceftriaxone: renal and biliary excretion and effect on the colon microflora. J Antimicrob Chemother. 1982;10:207–15.CrossRefPubMed
2.
Zurück zum Zitat Richards DM, Heel RC, Brogden RN, Speight TM, Avery GS. Ceftriaxone: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1984;27:469–527.CrossRefPubMed Richards DM, Heel RC, Brogden RN, Speight TM, Avery GS. Ceftriaxone: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1984;27:469–527.CrossRefPubMed
3.
Zurück zum Zitat Park HZ, Lee SP, Schy AL. Ceftriaxone-associated gallbladder sludge. Identification of calcium-ceftriaxone salt as a major component of gallbladder precipitate. Gastroenterology. 1991;100:1665–70.CrossRefPubMed Park HZ, Lee SP, Schy AL. Ceftriaxone-associated gallbladder sludge. Identification of calcium-ceftriaxone salt as a major component of gallbladder precipitate. Gastroenterology. 1991;100:1665–70.CrossRefPubMed
4.
Zurück zum Zitat Shiffman ML, Keith FB, Moore EW. Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterology. 1990;99:1772–8.CrossRefPubMed Shiffman ML, Keith FB, Moore EW. Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterology. 1990;99:1772–8.CrossRefPubMed
5.
Zurück zum Zitat Schaad UB, Tschappeler H, Lentze MJ. Transient formation of precipitations in the gallbladder associated with ceftriaxone therapy. Pediatr Infect Dis. 1986;5:708–10.CrossRefPubMed Schaad UB, Tschappeler H, Lentze MJ. Transient formation of precipitations in the gallbladder associated with ceftriaxone therapy. Pediatr Infect Dis. 1986;5:708–10.CrossRefPubMed
6.
Zurück zum Zitat Schaad UB, Wedgwood-Krucko J, Tschaeppeler H. Reversible ceftriaxone-associated biliary pseudolithiasis in children. Lancet. 1988;2:1411–3.CrossRefPubMed Schaad UB, Wedgwood-Krucko J, Tschaeppeler H. Reversible ceftriaxone-associated biliary pseudolithiasis in children. Lancet. 1988;2:1411–3.CrossRefPubMed
7.
Zurück zum Zitat Schaad UB, Suter S, Gianella-Borradori A, Pfenninger J, Auckenthaler R, Bernath O, et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. N Engl J Med. 1990;322:141–7.CrossRefPubMed Schaad UB, Suter S, Gianella-Borradori A, Pfenninger J, Auckenthaler R, Bernath O, et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. N Engl J Med. 1990;322:141–7.CrossRefPubMed
8.
Zurück zum Zitat Papadopoulou F, Efremidis S, Karyda S, Badouraki M, Karatza E, Panteliadis C, et al. Incidence of ceftriaxone-associated gallbladder pseudolithiasis. Acta Paediatr. 1999;88:1352–5.CrossRefPubMed Papadopoulou F, Efremidis S, Karyda S, Badouraki M, Karatza E, Panteliadis C, et al. Incidence of ceftriaxone-associated gallbladder pseudolithiasis. Acta Paediatr. 1999;88:1352–5.CrossRefPubMed
9.
Zurück zum Zitat Palanduz A, Yalcin I, Tonguc E, Guler N, Ones U, Salman N, et al. Sonographic assessment of ceftriaxone-associated biliary pseudolithiasis in children. J Clin Ultrasound. 2000;28:166–8.CrossRefPubMed Palanduz A, Yalcin I, Tonguc E, Guler N, Ones U, Salman N, et al. Sonographic assessment of ceftriaxone-associated biliary pseudolithiasis in children. J Clin Ultrasound. 2000;28:166–8.CrossRefPubMed
10.
Zurück zum Zitat Ozturk A, Kaya M, Zeyrek D, Ozturk E, Kat N, Ziylan SZ. Ultrasonographic findings in ceftriaxone: associated biliary sludge and pseudolithiasis in children. Acta Radiol. 2005;46:112–6.CrossRefPubMed Ozturk A, Kaya M, Zeyrek D, Ozturk E, Kat N, Ziylan SZ. Ultrasonographic findings in ceftriaxone: associated biliary sludge and pseudolithiasis in children. Acta Radiol. 2005;46:112–6.CrossRefPubMed
11.
Zurück zum Zitat Biner B, Oner N, Celtik C, Bostancioglu M, Tuncbilek N, Guzel A, et al. Ceftriaxone-associated biliary pseudolithiasis in children. J Clin Ultrasound. 2006;34:217–22.CrossRefPubMed Biner B, Oner N, Celtik C, Bostancioglu M, Tuncbilek N, Guzel A, et al. Ceftriaxone-associated biliary pseudolithiasis in children. J Clin Ultrasound. 2006;34:217–22.CrossRefPubMed
12.
Zurück zum Zitat Kong MS, Chen CY. Risk factors leading to ceftriaxone-associated biliary pseudolithiasis in children. Changgeng Yi Xue Za Zhi. 1996;19:50–4.PubMed Kong MS, Chen CY. Risk factors leading to ceftriaxone-associated biliary pseudolithiasis in children. Changgeng Yi Xue Za Zhi. 1996;19:50–4.PubMed
13.
Zurück zum Zitat Soysal A, Erasov K, Akpinar I, Bakir M. Biliary precipitation during ceftriaxone therapy: frequency and risk factors. Turk J Pediatr. 2007;49:404–7.PubMed Soysal A, Erasov K, Akpinar I, Bakir M. Biliary precipitation during ceftriaxone therapy: frequency and risk factors. Turk J Pediatr. 2007;49:404–7.PubMed
14.
Zurück zum Zitat Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM. Ceftriaxone-associated biliary pseudolithiasis in adults. Lancet. 1989;2:165.CrossRefPubMed Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM. Ceftriaxone-associated biliary pseudolithiasis in adults. Lancet. 1989;2:165.CrossRefPubMed
15.
Zurück zum Zitat Heim-Duthoy KL, Caperton EM, Pollock R, Matzke GR, Enthoven D, Peterson PK. Apparent biliary pseudolithiasis during ceftriaxone therapy. Antimicrob Agents Chemother. 1990;34:1146–9.CrossRefPubMedPubMedCentral Heim-Duthoy KL, Caperton EM, Pollock R, Matzke GR, Enthoven D, Peterson PK. Apparent biliary pseudolithiasis during ceftriaxone therapy. Antimicrob Agents Chemother. 1990;34:1146–9.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Cometta A, Gallot-Lavallee-Villars S, Iten A, Cantoni L, Anderegg A, Gonvers JJ, et al. Incidence of gallbladder lithiasis after ceftriaxone treatment. J Antimicrob Chemother. 1990;25:689–95.CrossRefPubMed Cometta A, Gallot-Lavallee-Villars S, Iten A, Cantoni L, Anderegg A, Gonvers JJ, et al. Incidence of gallbladder lithiasis after ceftriaxone treatment. J Antimicrob Chemother. 1990;25:689–95.CrossRefPubMed
18.
Zurück zum Zitat Zinberg J, Chernaik R, Coman E, Rosenblatt R, Brandt LJ. Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis. Am J Gastroenterol. 1991;86:1251–4.PubMed Zinberg J, Chernaik R, Coman E, Rosenblatt R, Brandt LJ. Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis. Am J Gastroenterol. 1991;86:1251–4.PubMed
19.
Zurück zum Zitat Bickford CL, Spencer AP. Biliary sludge and hyperbilirubinemia associated with ceftriaxone in an adult: case report and review of the literature. Pharmacotherapy. 2005;25:1389–95.CrossRefPubMed Bickford CL, Spencer AP. Biliary sludge and hyperbilirubinemia associated with ceftriaxone in an adult: case report and review of the literature. Pharmacotherapy. 2005;25:1389–95.CrossRefPubMed
20.
Zurück zum Zitat Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E. Single-dose ceftriaxone kinetics in functionally anephric patients. Clin Pharmacol Ther. 1983;33:633–41.CrossRefPubMed Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E. Single-dose ceftriaxone kinetics in functionally anephric patients. Clin Pharmacol Ther. 1983;33:633–41.CrossRefPubMed
21.
Zurück zum Zitat Bor O, Dinleyici EC, Kebapci M, Aydogdu SD. Ceftriaxone-associated biliary sludge and pseudocholelithiasis during childhood: a prospective study. Pediatr Int. 2004;46:322–4.CrossRefPubMed Bor O, Dinleyici EC, Kebapci M, Aydogdu SD. Ceftriaxone-associated biliary sludge and pseudocholelithiasis during childhood: a prospective study. Pediatr Int. 2004;46:322–4.CrossRefPubMed
22.
Zurück zum Zitat Sasaki Y, Aoki S, Aoki K, Achiwa K, Yama T, Kubota M, et al. Acute pancreatitis associated with the administration of ceftriaxone in an adult patient. Nihon Shokakibyo Gakkai Zasshi. 2009;106:569–75.PubMed Sasaki Y, Aoki S, Aoki K, Achiwa K, Yama T, Kubota M, et al. Acute pancreatitis associated with the administration of ceftriaxone in an adult patient. Nihon Shokakibyo Gakkai Zasshi. 2009;106:569–75.PubMed
23.
Zurück zum Zitat Stoeckel K, Koup JR. Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model. Am J Med. 1984;77:26–32.PubMed Stoeckel K, Koup JR. Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model. Am J Med. 1984;77:26–32.PubMed
24.
Zurück zum Zitat Cohen D, Appel GB, Scully B, Neu HC. Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis. Antimicrob Agents Chemother. 1983;24:529–32.CrossRefPubMedPubMedCentral Cohen D, Appel GB, Scully B, Neu HC. Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis. Antimicrob Agents Chemother. 1983;24:529–32.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Rivera M, Garcia-Herrera AL, Burguera V, Sosa-Barrios H, Palomares JR, Quereda C. Ceftriaxone-associated gallbladder pseudolithiasis in a PD patient. Perit Dial Int. 2011;31:97–9.CrossRefPubMed Rivera M, Garcia-Herrera AL, Burguera V, Sosa-Barrios H, Palomares JR, Quereda C. Ceftriaxone-associated gallbladder pseudolithiasis in a PD patient. Perit Dial Int. 2011;31:97–9.CrossRefPubMed
26.
Zurück zum Zitat Kutuya N, Ozaki Y, Okazaki T. A symptomatic child with ceftriaxone-associated biliary pseudolithiasis. J Med Ultrason. 2008;35:125–8.CrossRef Kutuya N, Ozaki Y, Okazaki T. A symptomatic child with ceftriaxone-associated biliary pseudolithiasis. J Med Ultrason. 2008;35:125–8.CrossRef
27.
Zurück zum Zitat Robertson FM, Crombleholme TM, Barlow SE, Verhave M, Brown D. Ceftriaxone choledocholithiasis. Pediatrics. 1996;98:133–5.PubMed Robertson FM, Crombleholme TM, Barlow SE, Verhave M, Brown D. Ceftriaxone choledocholithiasis. Pediatrics. 1996;98:133–5.PubMed
Metadaten
Titel
Risk factors of ceftriaxone-associated biliary pseudolithiasis in adults: influence of renal dysfunction
verfasst von
Aya Imafuku
Naoki Sawa
Akinari Sekine
Masahiro Kawada
Rikako Hiramatsu
Masayuki Yamanouchi
Eiko Hasegawa
Noriko Hayami
Jyunichi Hoshino
Yoshifumi Ubara
Kenmei Takaichi
Publikationsdatum
01.06.2018
Verlag
Springer Singapore
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 3/2018
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-017-1493-7

Weitere Artikel der Ausgabe 3/2018

Clinical and Experimental Nephrology 3/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.